Background and Aim: In psoriasis, the proteins Tumor Necrosis Factor (TNF) and interleukin-6 (IL-6) are overexpressed and play important roles in the disease's progression. For treating psoriasis, biological drugs that target TNF signaling are quite successful. Embryogenesis, tissue repair, cancer, neuronal survival, host defense, and inflammation are all dependent on progranulin (PGRN). By competing with TNF binding to TNFR1/2, PGRN inhibits TNF-mediated signaling pathways and has anti-inflammatory properties in inflammatory arthritis models. The current research seeks to study the relationship between serum PGRN / TNF - \(\alpha\)and psoriasis vulgaris activity. Subjects & Methods: This study’s subjects were categorized into 2 groups: group 1 with 35 patients with psoriasis vulgaris, and group 2 of 30 healthy subjects with matched age and sex. Results: We discovered a significant increase in PGRN and TNF-\(\alpha\)in cases versus control. And we have found a significant decrease in PGRN/TNF-\(\alpha\)ratio in cases versus control. We also detected significant differences between the Psoriasis Area Severity Index (PASI) degree and the levels of PGRN and TNF-\(\alpha\), as well as the PGRN/TNF-\(\alpha\)ratio. We discovered a negative significant correlation between PASI and PGRN/TNF-\(\alpha\)ratio. Conclusion: Atsttrin exhibited potent anti-inflammatory properties due to its three modified granulin motifs and their associated linker regions. In the treatment of rheumatoid arthritis and contact dermatitis, PGRN and its derivative Atsttrin may be a potential therapeutic drug.
